Podcasts about inc research

This week, we're joined by Jaspreet Grewal & Sabrina Ramkellawan, founders of Knowde Group - Canadian contract research organisation and hybrid consultancy specialising in plant-based therapeutics and psychedelics.In this episode, we explore the complexities of clinical trials within the cannabis industry, including barriers to entry, the three phases of clinical trials, how to navigate the regulatory landscape, and access to funding.About Jaspreet Grewal  MBA, MSc, CCRPJaspreet Grewal is an accomplished clinician, researcher and venture partner bringing over 15 years of experience to companies focused on the Life Sciences. Throughout her career, she has held various positions with increasing responsibilities in various healthcare roles resulting in a broad skillset and robust healthcare and investment network while working in Canada, the US, the UK, the Cayman Islands, and Bermuda. Jaspreet holds a Master's in Clinical Vision Sciences from Georgetown University, an Executive Certificate in Public Health from Harvard University and an MBA from the London School of Economics and Political Science.She is considered an expert in Healthcare and Regulatory Strategy and is a passionate advocate for building Alberta's Life Science ecosystem. She has successfully merged her expertise in innovation, research and finance to become a dynamic leader not only nationally but internationally. Her current roles and affiliations include:Co-Founder & CEO, Knowde Group (Canada, UK and Australia)Founder & CEO, Venn Consulting (Canada)Board Director, BioAlbertaEntrepreneur in Residence, Innovate Calgary (Medical Cannabis)Global Lifesciences Consultant, Calgary Economic DevelopmentExternal Advisor to the Vi Riddell Pain & Rehabilitation Centre, Alberta Children's Hospital  About Sabrina RamkellawanSabrina has over 20 years of clinical research experience in pharma, medical devices, natural health products and plant-based therapeutics including cannabinoids. She has held positions at or advised some top pharmaceutical, cannabis, psychedelic, and research companies. Sabrina has conducted and supported 11 cannabis research studies to date. She has previous experience leading operations at large scale global Contract Research Organisations including INC Research (now Syneos Health) as well as building successful speciality clinics. Sabrina is also passionate about education and has helped to build and currently teaches the first Certified Cannabis Educator Program at Michener Institute of Education at UHN. She has been and continues to be a speaker in the area of research and plant-based medicine. Prior to her role at Knowde Group, she was the VP of Clinical Affairs at TerrAscend Canada which is a licensed producer. In her role as Chief Operating Officer at Knowde Group, she is focused on all aspects of conducting research specialising in plant-based therapeutics and psychedelics. ResourcesJoin Sabrina on LinkedIn: https://www.linkedin.com/in/sabrinaramkellawan/?originalSubdomain=caJoin Jaspreet on LinkedIn: https://www.linkedin.com/in/jkgrewal/Follow Knowde Group on Twitter: https://twitter.com/knowdegroupKnowde Group's Website: https://www.knowdegroup.com/ 

Dr. Neal Kassell, founder and chairman of the Focused Ultrasound Foundation, discusses focused ultrasound, a revolutionary, non-invasive, highly disruptive technology approved in the United States to treat essential tremor, tremor-dominant Parkinson's disease, uterine fibroids, pain from bone metastases, and prostate cancer. The technology is in various stages of research and development around the world for more than 100 diseases and conditions, including ALS, Alzheimer's, hypertension, and tumors of the brain, liver, breast, and pancreas. He talks about how this therapy is poised to impact the way we treat some of our most elusive diseases. Dr. Kassell is the founder and chairman of the Focused Ultrasound Foundation and former Co-Chair of Neurosurgery at the University of Virginia. He has published more than 500 scientific papers and book chapters, and his research has been supported by over $30 million in NIH and industry grants and contracts. A member of numerous medical societies in the United States and abroad, he has served on many standing and ad hoc committees of the National Institutes of Health and in an editorial capacity for a variety of academic journals. In April 2016, he was named to the Blue Ribbon Panel of Vice President Joe Biden's Cancer Moonshot Initiative. Dr. Kassell is a founder of numerous private ventures including Interax, Inc.; the Virginia Neurological Institute; Multimedia Medical Systems, Inc.; the Neuroclinical Trials Center; the NeuroVenture Fund; and MedSpecialists.net. He has served on a number of corporate and not-for-profit boards, including Eclypsis Corporation; INC Research; the Prostate Cancer Foundation; Insightec, Ltd.; the Expedition Trust Company; Tuesday Evening Concert Series and Virginia National Bank, and is currently a director of the Focused Ultrasound Foundation. He is a shareholder in Insightec, Ltd., where he also served on the board until 2012. Dr. Kassell received his undergraduate and medical education at the University of Pennsylvania. #FocusedUltrasoundTechnology

Dr. Clare Grace, Chief Patient Officer at Parexel, a leading Clinical Research Organization (CRO) discusses a report titled "Discussions on Diversity" that includes key takeaways regarding candid discussions on the topic of racial and ethnic diversity in clinical trials. As Chief Patient Officer for Parexel, Dr. Grace leads Parexel's global patient advocacy and site efforts, including patient engagement strategies and efforts to enhance clinical trial diversity as well as new, innovative approaches to help teams and customers work more effectively with investigative sites. Most recently she served as Vice President, Site & Patient Access at Syneos Health, formerly INC Research, where she oversaw all departments responsible for patient engagement, feasibility, site identification, strategic site relations and investigator payments. Her experience also includes senior-level patient and site-focused leadership roles with PPD, Astra Zeneca and Antisoma. With more than 20 years of experience in the CRO and biopharmaceutical industries, Dr. Grace was recognized in 2018 by PharmaVoice as one of the top 100 most inspirational leaders in the pharmaceutical industry. She earned a doctorate in Molecular Oncology from the University of Manchester Institute of Science and Technology and a bachelor's degree in applied biochemistry from Liverpool John Moores University, both in England. Dr. Grace is active in several global and national-level advisory groups, including the Society for Clinical Research Sites (SCRS) and the SCRS Leadership Council. #Parexel

In this episode of Glassdoor Reviews, we review the now number two CRO in the clinical research space Syneos Health which was a merger between Inc Research and Inventiv Health. These two CRO's became one in the merger and the merger has taken place just last year. The origin of Syneos has recently just celebrated their one year old anniversary. I hope you enjoy this breakdown of the number 2 CRO in the space. Don't forget to Subscribe for new content! Subscribe: https://youtube.com/eliteclinicalrese... Call or Text: 910-502-3732 Email: eliteclinicalgroup@gmail.com Podcast: https://anchor.fm/clinical-research-p... Steemit: https://steemit.com/@ecrgmedia Advertise: eliteclinicalgroup@gmail.com Watch: » Industry News: https://goo.gl/fNXpQ5 » All Videos: https://goo.gl/87XEFW » Interview Recaps: https://goo.gl/wJsk6W » Glassdoor Reviews: https://goo.gl/AbQzqe We do: » Insider Interviews » Resume Reviews » Question and Answer » Discuss all things Clinical Research » News and Product Reviews » Education --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/clinical-research-podcast/message Support this podcast: https://anchor.fm/clinical-research-podcast/support

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Novartis, Antares Vision, Syneos Health, Celgene, Impact Biomedicines, Pfizer, Roche, Techdow Pharma, Spark Therapeutics, Chiltern.Persone: Elisabeth Barrett (Novartis), Robert Kowalski (Novartis), Robert Landewé (Amsterdam Rheumatology Center).Nuove terapie: secukinumab, adalimumab, antidemetilasi & antideacetilasi, palbociclib, ocrelizumab, Inhixa, Luxturna.Patologie: Alzheimer, Parkinson, spondilite anchilosante, artrite psoriasica, cancro, tumore al seno, sclerosi multipla, trombosi, retinopatia ereditaria.Lavoro: CRA, Regulatory Affairs.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Novartis, Antares Vision, Syneos Health, Celgene, Impact Biomedicines, Pfizer, Roche, Techdow Pharma, Spark Therapeutics, Chiltern.Persone: Elisabeth Barrett (Novartis), Robert Kowalski (Novartis), Robert Landewé (Amsterdam Rheumatology Center).Nuove terapie: secukinumab, adalimumab, antidemetilasi & antideacetilasi, palbociclib, ocrelizumab, Inhixa, Luxturna.Patologie: Alzheimer, Parkinson, spondilite anchilosante, artrite psoriasica, cancro, tumore al seno, sclerosi multipla, trombosi, retinopatia ereditaria.Lavoro: CRA, Regulatory Affairs.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

What's in a name? Quite a lot, actually, despite what Shakespeare says. When it comes to a merger, this can be even more important.  With research showing that up to 80% of mergers fail – and one major reason being clashing corporate cultures during post-merger integration – choosing a name and brand that the entire organization can get behind is critical to success. In this episode, listen to Kristen Spensieri of Syneos Health and Joe Daley of Syneos Health branding firm Addison Whitney discuss how the company is walking the talk – rebranding its own organization after the 2017 merger of INC Research and inVentiv Health, and how these principles can be applied to any company going through a rebrand. Listen to Part 2 of our Naming series here. See our full list of podcast episodes here.   The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you. Syneos Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any Syneos Health clients, customers or other contacts.

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: AstraZeneca, Aspen, Genenta Science, QuintilesIMS, LabCorp, Covance, PPD, Icon, INC Research, inVentiv Health, PRA Health Sciences, Parexel, BioClinica, Medpace, Premier Research, Teva Pharmaceuticals, Lundbeck, FDA, Amgen, Persone: Pierluigi Paracchi (Genenta Science), Luigi Naldini (Genenta Science) e Bernhard Gentner (Genenta Science), Guido Guidi (Genenta Science), Kenneth C. (Genenta Science), Kare Schultz (Teva Pharmaceuticals), Vytenis Andriukaitis (European Commissioner for Health and Food Safety), Jean-Pierre Bourguignon (European Research Council), Andrea Fontanella (FADOI).Nuove terapie: Mvasi, olaratumab.Patologie: sepsi, Parkinson, cancro, sarcoma.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: AstraZeneca, Aspen, Genenta Science, QuintilesIMS, LabCorp, Covance, PPD, Icon, INC Research, inVentiv Health, PRA Health Sciences, Parexel, BioClinica, Medpace, Premier Research, Teva Pharmaceuticals, Lundbeck, FDA, Amgen, Persone: Pierluigi Paracchi (Genenta Science), Luigi Naldini (Genenta Science) e Bernhard Gentner (Genenta Science), Guido Guidi (Genenta Science), Kenneth C. (Genenta Science), Kare Schultz (Teva Pharmaceuticals), Vytenis Andriukaitis (European Commissioner for Health and Food Safety), Jean-Pierre Bourguignon (European Research Council), Andrea Fontanella (FADOI).Nuove terapie: Mvasi, olaratumab.Patologie: sepsi, Parkinson, cancro, sarcoma.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: INC Research, inVentiv Health, GSK, EMA, QuintilesIMS, PRA, Assobiotec, EUSA Pharma.Persone: Micheal Bell (inVentiv Health), Alistar Macdonald (INC Research), Rino Rappuoli (GKS), Guido Rasi (EMA), Beatrice Lorenzin (Ministro della Salute), Manlio Florenzano (Italian Biosimilars Group), Mark Sorrentino (PRA), Riccardo Palmisano (Assobiotec), Bruno Daniele (Ospedale Rummo di Benevento). Nuove terapie: dinutuximab beta, nivolumab.Patologie: neuroblastoma, tumore al fegato.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: INC Research, inVentiv Health, GSK, EMA, QuintilesIMS, PRA, Assobiotec, EUSA Pharma.Persone: Micheal Bell (inVentiv Health), Alistar Macdonald (INC Research), Rino Rappuoli (GKS), Guido Rasi (EMA), Beatrice Lorenzin (Ministro della Salute), Manlio Florenzano (Italian Biosimilars Group), Mark Sorrentino (PRA), Riccardo Palmisano (Assobiotec), Bruno Daniele (Ospedale Rummo di Benevento). Nuove terapie: dinutuximab beta, nivolumab.Patologie: neuroblastoma, tumore al fegato.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: AIFA, EMA, Aristo Pharma, QuintilesIMS, PSI CRO, INC Research, Chiltern, Parexel, ICON, PPD, Amgen, PTC Therapeutics.Persone: Giuseppe Sala (Sindaco di Milano), Giorgio Foresti (Aristo Pharma), Filippo Boschetti (QuintilesIMS), Marcello D’Amelio (Università Campus Bio-Medico di Roma), Glenis Willmott (Parlamento Europeo), Eugenio Mercuri (Università Cattolica di Roma), Manuela Maronati (PTC Therapeutics).Nuove terapie: Blinatumomab, Ataluren.Patologie: depressione, Alzheimer, leucemia linfoblastica acuta, distrofia di Duchenne.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: AIFA, EMA, Aristo Pharma, QuintilesIMS, PSI CRO, INC Research, Chiltern, Parexel, ICON, PPD, Amgen, PTC Therapeutics.Persone: Giuseppe Sala (Sindaco di Milano), Giorgio Foresti (Aristo Pharma), Filippo Boschetti (QuintilesIMS), Marcello D’Amelio (Università Campus Bio-Medico di Roma), Glenis Willmott (Parlamento Europeo), Eugenio Mercuri (Università Cattolica di Roma), Manuela Maronati (PTC Therapeutics).Nuove terapie: Blinatumomab, Ataluren.Patologie: depressione, Alzheimer, leucemia linfoblastica acuta, distrofia di Duchenne.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/

Thought Leaders: Jessica Albano, PhD, MPH, Senior Director, Epidemiology, Post Approval & Strategic Services, and Dr. Vikki Brown, Medical Director for the Post-Approval and Strategic Services division of INC Research, Inc.In this episode, our experts discuss the primary challenges regarding women's health in clinical research. They also cover pregnancy registries and lactation studies, as well as available regulatory guidance related to this type of research.For more information about INC Research, visit www.incresearch.com.Play Podcast.For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.

Date Posted: 5/31/2011Size: 5.56MBLength: 00:12:09Thought Leader: Tim Dietlin, VP of Alliance Development, INC ResearchIn this episode, Mr. Dietlin discusses a burgeoning concept called the Networked Drug Development Alliance, what it is, what's driving it, and how they improve the process for pharmaceutical companies and investors.Play PodcastFor more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.

INC Research CEO James Ogle tells Outsourcing-pharma.com that the acquisition of fellow CRO Kendle was about building a presence in emerging trial hotspots and pharmaceutical markets.

INC Research CEO James Ogle tells Outsourcing-pharma.com that the acquisition of fellow CRO Kendle was about building a presence in emerging trial hotspots and pharmaceutical markets.

Date Posted: 05/11/2010Size: 6.88MBLength: 00:15:02Thought Leader: Tim Dietlin, VP of Alliance Development, INC ResearchIn this episode Mr. Dietlin talks about Clinical Delivery Alliances; what they are and how they can benefit the drug development process.Play PodcastDownload WhitepaperFor more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.

INC Research is partnering with invivodata to add ePRO to its offering, selecting the eClinical firm over its competitors in part because it understands the “aggressive” approach the CRO takes.